News

Caldic announces partnership with BIO-CAT to bring innovative probiotics to the Companion Animal Health and Nutrition industry

BIO-CAT, Inc., an industry leading probiotic manufacturer, has agreed to partner with global distribution solutions provider Caldic North America to bring their proprietary probiotic strains and OPTIFEED® branded solutions to the Companion Animal Health and Nutrition market in North America. This agreement secures a rapid go-to-market strategy for BIO-CAT, leveraging Caldic’s leadership position in the Companion Animal market as a provider of value-add antioxidant, vitamin, mineral, and ingredient solutions.

Founded in Keswick, Virginia, BIO-CAT is an industry-leading expert in specialty enzyme and probiotic formulations. The company offers an extensive range of single-to-multi-enzyme blends and unique microbial solutions for better animal digestive health. BIO-CAT Microbials, located in Shakopee Minnesota, is BIO-CAT’s vertically integrated FDA registered and SQF certified (human-grade) U.S. fermentation facility. Their AAFCO-listed OPTIFEED® probiotic strains are premium, safe, effective, and have shown physiological benefits to companion animals in support of their gastrointestinal and digestive health; similar to the benefits they deliver to humans. Future expansion of the OPTIFEED® line of enzymes will further support digestive health, enhancing the nutritional value of pet food, and can be used in ingredient processing and flavor development.

“This partnership with BIO-CAT significantly strengthens Caldic’s existing Companion Animal portfolio,” says Liz Parker, Director of Companion Animal Health & Nutrition, Caldic North America, “adding a range of innovative and customizable solutions to inspire quality pet food and health. As the importance of pet companionship is widely recognized, domestic animal owners are increasingly keen to provide their pets with nutritionally high-performing food, treats and supplements. The expert know-how our R&D team has acquired in pet food when formulating with our antioxidants range, Dadex®, and our custom vitamin and mineral blends, Daminaide®, will greatly benefit the solutions we can deliver across North America while partnering with BIO-CAT.”

“BIO-CAT Microbials’ expertise in probiotic strain development and fermentation is a great match for Caldic’s exceptional distribution solutions,” says Chris Schuler, President and CEO of BIO-CAT. “We value Caldic’s commitment to the Companion Animal space and their ability to scale our OPTIFEED® probiotic business within their customer base. We look forward to a successful collaboration and exclusive partnership with Caldic.”

Recent News

07/15/2026

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin